441796-08-3

Basic information

• Product Name: N-[5-(4-bromophenyl)-6-(2-hydroxyethoxy)-4-pyrimidinyl]-N'-benzyl-sulfamide
• Synonyms: N-[5-(4-bromophenyl)-6-(2-hydroxyethoxy)-4-pyrimidinyl]-N'-benzyl-sulfamide
• CAS NO: 441796-08-3
• Molecular Weight: 479.354
• Mol File: 441796-08-3.mol

Chemical Properties

• CAS DataBase Reference: N-[5-(4-bromophenyl)-6-(2-hydroxyethoxy)-4-pyrimidinyl]-N'-benzyl-sulfamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[5-(4-bromophenyl)-6-(2-hydroxyethoxy)-4-pyrimidinyl]-N'-benzyl-sulfamide(441796-08-3)
• EPA Substance Registry System: N-[5-(4-bromophenyl)-6-(2-hydroxyethoxy)-4-pyrimidinyl]-N'-benzyl-sulfamide(441796-08-3)

Safety Data

• Hazardous Substances Data: 441796-08-3(Hazardous Substances Data)

Upstream product

• 441797-42-8 N-[5-(4-bromophenyl)-6-chloro-4-pyrimidinyl]-N'-benzyl-sulfamide 
• 107-21-1 ethylene glycol 
• 100-46-9 benzylamine 
• 41841-16-1 (4-bromo-phenyl)-acetic acid methyl ester 
• 1878-68-8 2-(4-bromophenyl)-acetic acid 
• 146533-41-7 5-(4-bromophenyl)-4,6-dichloropyrimidine 
• 149506-35-4 2-(4-bromophenyl)-malonic acid dimethyl ester 
• 706811-25-8 5-(4-bromophenyl)-4,6-dihydroxypyrimidine 
• 147000-78-0 N¹-BOC-N³-benzylsulfamide 
• 14101-58-7 N-benzylsulfamide 

Downstream Products

• 441796-09-4 benzylsulfamic acid {5-(4-bromophenyl)-6-[2-(5-bromopyrimidin-2-yloxy)-ethoxy]-pyrimidine-4-yl}-amide 
• 1103522-45-7 ACT-132577 

Relevant articles and documents

The discovery of N -[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy] ethoxy]-4-pyrimidinyl]- N ′-propylsulfamide (macitentan), an orally active, potent dual endothelin receptor antagonist

Starting from the structure of bosentan (1), we embarked on a medicinal chemistry program aiming at the identification of novel potent dual endothelin receptor antagonists with high oral efficacy. This led to the discovery of a novel series of alkyl sulfamide substituted pyrimidines. Among these, compound 17 (macitentan, ACT-064992) emerged as particularly interesting as it is a potent inhibitor of ETA with significant affinity for the ET B receptor and shows excellent pharmacokinetic properties and high in vivo efficacy in hypertensive Dahl salt-sensitive rats. Compound 17 successfully completed a long-term phase III clinical trial for pulmonary arterial hypertension.

4-PYRIMIDINESULFAMIDE DERIVATIVE

The invention relates to the compound of structural formula (I) and the salts thereof. Said compound is useful as endothelin receptor antagonist. The invention further relates to a process for preparing said compound.

4-PYRIMIDINESULFAMIDE DERIVATIVE

The invention relates to the compound of structural formula (I) and the salts thereof. Said compound is useful as endothelin receptor antagonist. The invention further relates to a process for preparing said compound.